DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Time to Buy?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price gapped up prior to trading on Friday . The stock had previously closed at $23.04, but opened at $24.70. DBV Technologies shares last traded at $24.4450, with a volume of 189,559 shares.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research report on Thursday, December 18th. Zacks Research upgraded DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a report on Wednesday, December 17th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Finally, Citizens Jmp raised their target price on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, DBV Technologies has an average rating of “Moderate Buy” and a consensus price target of $35.38.

DBV Technologies Stock Up 9.8%

The firm has a market cap of $1.02 billion, a P/E ratio of -4.86 and a beta of -1.17. The firm has a fifty day moving average of $17.32 and a 200-day moving average of $13.44.

Insider Activity at DBV Technologies

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares in the company, valued at $41,688,039.20. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. GAMMA Investing LLC boosted its stake in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares in the last quarter. Millennium Management LLC lifted its stake in shares of DBV Technologies by 26.1% in the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after acquiring an additional 69,849 shares during the period. Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the 3rd quarter valued at $220,000. Two Sigma Investments LP acquired a new stake in DBV Technologies during the third quarter worth approximately $167,000. Finally, DLD Asset Management LP bought a new position in DBV Technologies during the third quarter worth $250,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.